The U.S. Supreme Court has turned aside the bid by pharmaceutical maker Eli Lilly to not only toss out a $183 million judgment against the company, but also put a dent in a system the company says unconstitutionally permits "private bounty hunters" to use questionable legal claims to extract big paydays in the name of the government.

On May 18, the high court formally denied Eli Lilly's appeal petition.

This report was produced by Legal Newsline and distributed by The Center Square as part of a content-sharing agreement. Reach editor John O’Brien at john.obrien@therecordinc.com.

Originally published on legalnewsline.com, part of the BLOX Digital Content Exchange.